 |
[Alpha Biz=(Chicago) Reporter Paul Lee] GC Biopharma announced on June 3 that it has signed a contract to supply IVIG-SN 5%, an immunogloblin blood drug, with its Brazilian partner Blau Farmaceutica on June 30.
Through this contract, GC Biopharma will supply 90.48 million dollars (about 119.4 billion won) worth of supplies to Brazil. The contract period is a total of five years until June 29, 2028, and the contract amount is set first as an estimated amount for supply by December 31, 2025.
Brazil is the largest blood product market in South America, and as of 2022, the immune globlin market is about $ 270 million.
GC Biopharma has been supplying blood products to the Brazilian government's drug bidding and private markets since 2015. In addition, 12 blood products, including albumin, are currently exported to 32 countries around the world, including Argentina, Uruguay and Vietnam.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
